CohBar Appoints Effie Tozzo, Ph.D. to Its Board of Directors
12 juil. 2022 09h00 HE
|
CohBar, Inc.
MENLO PARK, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its...
CohBar to Participate at Upcoming Conferences in June 2022
07 juin 2022 09h00 HE
|
CohBar, Inc.
MENLO PARK, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its...
CohBar to Present at the H.C. Wainwright Global Investment Conference
19 mai 2022 16h02 HE
|
CohBar, Inc.
MENLO PARK, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its...
CohBar Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Progress
16 mai 2022 16h01 HE
|
CohBar, Inc.
MENLO PARK, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its...
CohBar Announces Extension of Nasdaq Compliance Period and Summarizes 2022 Annual Meeting Proposal
12 mai 2022 09h00 HE
|
CohBar, Inc.
MENLO PARK, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) (the “Company”), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides...
CohBar to Announce 2022 First Quarter Financial Results and Provide Business Update on May 16, 2022
02 mai 2022 09h00 HE
|
CohBar, Inc.
MENLO PARK, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its...
CohBar Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
29 mars 2022 16h01 HE
|
CohBar, Inc.
MENLO PARK, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its...
CohBar to Announce 2021 Fourth Quarter and Full-Year Financial Results and Provide Business Update on March 29, 2022
15 mars 2022 09h00 HE
|
CohBar, Inc.
MENLO PARK, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its...
CohBar to Present at H.C. Wainwright BIOCONNECT Conference
03 janv. 2022 09h00 HE
|
CohBar, Inc.
MENLO PARK, Calif., Jan. 03, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company exploiting the power of the mitochondria and the peptides encoded in its...
CohBar Announces Changes to its Board of Directors and R&D Leadership
17 déc. 2021 09h00 HE
|
CohBar, Inc.
Founding board members transition to reconstituted Scientific Advisory Board Kent Grindstaff, Ph.D. appointed as Senior Vice President of Research MENLO PARK, Calif., Dec. 17, 2021 (GLOBE...